News

AbstractBackground Cardiac amyloidosis (CA) is frequently preceded by soft tissue infiltration, manifesting as orthopaedic "red flags" such as carpal tunnel…

Cardiovascular disease, the leading cause of deathTrusted Source globally, has not yet had an early-detection test — until now. On June 22, the Food and Drug…

AbstractInterpreting composite endpoints in cardiovascular drug development is a key challenge, particularly when events of different clinical relevance are…

Long-term treatment with diflunisal may help slow disease progression in people with hereditary transthyretin amyloidosis (hATTR), according to a Swedish real-world…

AbstractCardiac amyloidosis is a clinical condition characterized by deposition of amyloid fibrils in the myocardium, leading to increased left ventricular wall…

There are many well-known benefits of strength training, including stronger bones and muscles, improved heart health, and decreased abdominal fat.A new study…

AbstractBackground: Cardiac Amyloidosis (CA), specifically Transthyretin Amyloid Cardiomyopathy (ATTR-CM), is an under-recognized, progressive, and fatal disease.…

Many patients evaluated for two common forms of cardiac amyloidosis never received the testing recommended to confirm or rule out the diseases, a large analysis of…

AbstractIn a first-in-human trial (NI006-101), the monoclonal antibody cliramitug, targeting misfolded transthyretin, demonstrated a favorable safety profile and…

For East Asian adults with transthyretin amyloid cardiomyopathy (ATTR-CM), the approved therapy Amvuttra (vutrisiran) is a safe and effective treatment, with…